Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

4 big analyst cuts: Urban Outfitters downgraded ahead of Q2

Published 15/08/2023, 12:04
Updated 15/08/2023, 12:04
© Reuters.

Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades at Urban Outfitters, Keysight Technologies, Design Therapeutics, and Avid Technology.

InvestingPro subscribers got this news first. Never miss another market-moving headline.

Urban Outfitters downgraded at Citi ahead of Q2

Citi downgraded Urban Outfitters (NASDAQ:URBN) to Neutral from Buy with a price target of $40.00 (from $36.00), as reported in real time on InvestingPro.

The bank expects the company to beat Q2 earnings estimates and provide strong guidance next Tuesday but believes the company's risk/reward now looks balanced.

"We expect Anthro/FP will continue to show comp strength this year and that UO will improve sequentially in 2H. However, we believe the UO brand will be slower to turn around given fashion inconsistency (resulting in lower customer loyalty) and a tougher competitive landscape, ultimately limiting possible upside to EPS beyond what is already anticipated by the market."

Keysight Technologies cut to Underperform at BofA Securities

BofA Securities downgraded Keysight Technologies (NYSE:KEYS) to Underperform from Neutral and cut its price target to $148.00 from $163.00 ahead of the upcoming Q3 earnings report on Thursday, noting that Keysight's order trends are likely to get worse before they get better.

The bank anticipates a more significant decline in Q3 orders than what consensus forecasts and sees downside risks to 2024 estimates. “While we view Keysight as a well-managed market share leader, the macro backdrop is likely to limit EPS growth,” added BofA.

Two more downgrades

After providing business updates and outlining upcoming milestones within its clinical and research-stage pipeline of novel GeneTAC™ small molecules, as well as announcing its Q2 results, Design Therapeutics (NASDAQ:DSGN) witnessed its stock plummet by more than 40% pre-market today. As a consequence, the company received two downgrades from Wall Street analysts today.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

RBC Capital downgraded the company to Sector Perform from Outperform and cut its price target to $7.00 from $23.00. Meanwhile, SVB MoffettNathanson downgraded to Market Perform from Outperform with a price target of $6.00 (from $22.00).

Truist Securities downgraded Avid Technology (NASDAQ:AVID) to Hold from Buy and cut its price target to $27.05 from $45.00.

Last week, the company was downgraded by two other firms, Northland Capital Markets and B.Riley, following its Q2 earnings announcement.

Get ready to supercharge your investment strategy with our exclusive discounts.

Don't miss out on this limited-time opportunity to access cutting-edge tools, real-time market analysis, and expert insights. Join InvestingPro today and unlock your investing potential. Hurry, the Summer Sale won't last forever!

summer sale

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.